科研之友
微信
新浪微博
Facebook
分享链接
摘要
Based on the author’’s practical experience and clinical information, this article evaluates the common therapeutic drugs for COVID-19. It is suggested that prophylactic use of antibacterial drugs should be strictly restricted; corticosteroid therapy should only be used in patients who have developed lung injury and pay attention to the individual differences in drug dosage and course of treatment; the trials of antiviral drugs should be more carefully and make a conclusion as soon as possible whether the recommended drugs should continue to be used to avoid unnecessary effects of drugs.
